GB Patent

GB1430942A — 21-substituted 3alpha-hydroxy pregnanes

Assigned to Glaxo Laboratories Ltd · Expires 1976-04-07 · 50y expired

What this patent protects

3 alpha -Hydroxy-5 alpha ,ss-pregnan- and -19-norpregnan-20-ones which have in position 21 a substituent selected from cyano, azido and cycloamino and which can additionally be substituted in position 11 by another oxo group and can have in positions 2 alpha , 2ss, 3ss and 16 oth…

USPTO Abstract

3 alpha -Hydroxy-5 alpha ,ss-pregnan- and -19-norpregnan-20-ones which have in position 21 a substituent selected from cyano, azido and cycloamino and which can additionally be substituted in position 11 by another oxo group and can have in positions 2 alpha , 2ss, 3ss and 16 other substituents defined in Claims 1, 5 and 8, and which can additionally contain a double bond in the 1,2 and/or 4,5 position, have anaesthetic effects and provide short induction times. They are prepared by reacting a corresponding steroid which has in position 21 an easily eliminated radical with a compound which supplies cyanide or azide ions or with an appropriate cyclic amine.

Drugs covered by this patent

Patent Metadata

Patent number
GB1430942A
Jurisdiction
GB
Classification
—
Expires
1976-04-07
Drug substance claim
No
Drug product claim
No
Assignee
Glaxo Laboratories Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.